RE:spammers like these ones must be so frustrated they Still waiting for new analyst reports and price targets. They won't publish them as Leeds Jones Gable already baked this money into their $4 target and commented that there is nothing to do a discounted cash flow analysis as they have no indications to work on nor any time line. I bet Piper Sandler doesn't even cover Liminal anymore after their $22 price target was dashed by IPF stoppage.
https://leedejonesgable.com/wp-content/uploads/LMNL_2021_06_07.pdf
check it out captain and your 3 other boardnames Newcamo Realstocky Tommyjones
The firm has not yet indicated if a supplemental fibrotic or metabolic disease could emerge at ‘4050’s target indication or if ‘4050 development will be discontinued in deference to other pipeline agents, perhaps PBI-4425 or PBI-4547 that we assume share similar pharmacologic properties with ‘4050 and on which Liminal has published independent anti-fibrosis preclinical data in abstract form. But new voucher-derived capital if/when received will provide Liminal with sufficient financial flexibility to make more aggressive decisions on pipeline configuration in coming quarters.
Accordingly, though it seems likely that LMNL shares will experience positive near-term momentum on the Ryplazim FDA approval just conferred and on the notional value of the Pediatric Review Voucher ascribed to it, our model does not incorporate any longer-term revenue-based economic benefit from the drug beyond the bolus of cash it could generate. Furthermore, our model and financial forecasts are in flux as we determine the residual value of PBI-4050 and its analogs in medical markets that no longer include lung fibrosis or Alstrom syndrome. We do expect Liminal to complete its ongoing 72-patient multiple ascending dose Phase I trial, probably by end-of-year. For now, we are maintaining our HOLD rating and one-year PT of C$4.00
captsecord wrote: didnt load up like myself last 2 weeks....good.....i enjoy watching them beg today. +29% and vol 26,5M..... me and others told them the voucher cash was imminent as it was to be paid before closing of deal with kedrion, they called me a pumper. Guess i was correct too! Still a good price today, market cap only 112M$ ...voucher casg alone is 100M$.......................excellent buy for next days as the news rolls with analysts etc